Latest news
Raymond James Sticks to Its Buy Rating for Trevi Therapeutics (TRVI) - The Globe and MailThe Globe and Mail · Sat, 08 Aug 2026 13:38:00 GMTTrevi Therapeutics (TRVI) Receives a New Rating from B. Riley Securities - The Globe and MailThe Globe and Mail · Sat, 08 Aug 2026 13:23:00 GMTQ2 2026 Trevi Therapeutics Inc Earnings Call Transcript - GuruFocusGuruFocus · Sat, 08 Aug 2026 12:29:57 GMTOppenheimer Maintains Trevi Therapeutics(TRVI.US) With Buy Rating, Raises Target Price to $25 - MoomooMoomoo · Sat, 08 Aug 2026 07:14:59 GMTTrevi Therapeutics (NASDAQ:TRVI) Announces Earnings Results, Hits Estimates - MarketBeatMarketBeat · Fri, 07 Aug 2026 23:12:38 GMTTrevi Therapeutics Q2 Earnings Call Highlights - MarketBeatMarketBeat · Fri, 07 Aug 2026 18:15:45 GMTTrevi Therapeutics, Inc. Stock 12‑Month Price Target Raised to $29.17, Implies 58% Upside - TradingViewTradingView · Fri, 07 Aug 2026 17:20:32 GMTTRVI Maintains Overweight Rating -- Price Target Raised to $30 b - GuruFocusGuruFocus · Fri, 07 Aug 2026 14:43:07 GMT